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December 8, 2009:2337–41ariatric surgery on cardiovascular risk factors and quality of
ife (1).
In 1995, the Stent or Surgery trial was initiated, and subse-
uently compared coronary artery bypass surgery with stent-
ssisted percutaneous coronary intervention in patients with mul-
ivessel coronary artery disease. The study’s main report was
ublished in 2002 (2), and according to the clinical trials website,
he study has been completed since 2007.
In 2005, the Stenting Of Saphenous vein grafts trial was
nitiated to compare a paclitaxel-eluting with a similar bare-metal
tent in patients undergoing saphenous vein graft stenting. The
tudy’s primary results were published in 2009 (3).
Although it was never our intention to infringe on the Stent or
urgery trial’s acronym, we apologize to the Stent or Surgery
nvestigators if they feel that a copyright infringement occurred.
e would like to highlight, however, that our study was done in
different era, for a different reason, and in a different patient
opulation.
Would adding additional trial regulations, such as “expiration
ates for trial names” or additional oversight of the authors and
ditors improve the trial result reporting process? Should all the
ngoing SOS trials change their names? And should future trials
e prohibited from using acronyms from trials previously used?
ntil these questions are answered, we can only hope that the
issimilar nature of the trials serves to limit any confusion that
ight result from repeated use of the same acronym.
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n Defense of
ntimicrobial Prophylaxis
or Prevention of Infective
ndocarditis in Patients With
ypertrophic Cardiomyopathy
e read with particular interest Bach’s viewpoint editorial and
ritique (1) of the recent American Heart Association (AHA)
evised recommendations for antimicrobial prevention of infec-
ive endocarditis (2). The “new” recommendations, which
epresent a striking change from the original guidelines fol-
owed for more than 50 years (1–5), are based largely on 2 risk
ersus benefit assumptions: 1) significant mortality or morbidity
e.g., anaphylaxis) associated with prophylactic antibiotic ther-
py; and 2) a lack of evidence (particularly, randomized trials)
upporting the efficacy of antibiotic prophylaxis in the preven-
ion of infective endocarditis.
Our concern regarding this debate is focused on hypertrophic
ardiomyopathy (HCM) (6), a disease in which infective endocar-
itis is a well-documented and usually profound complication
6–9). Indeed, a survey of the PubMed archives identified 32
apers detailing the prevalence and the sometimes serious clinical
onsequences of endocarditis in HCM patients. While infective
ndocarditis is uncommon within the overall HCM population
8), when it does occur, its impact on valvular and cardiac function
nd risk for systemic emboli is usually consequential (7–9). Most
eported cases have been associated with left ventricular outflow
ract obstruction (vegetations most commonly appear on the
hickened anterior mitral leaflet or adjacent surface of proximal
entricular septum), and we wish to underscore that fully 70% of
CM patients have the propensity to develop outflow obstruction
t rest or with physiologic exercise (10).
We believe that the reversal of the “old” and familiar AHA
uidelines on antimicrobial prophylaxis was an unfortunate mistake
or patients with HCM, and indeed substantial confusion and
ncertainty surrounding this issue has been created within the
ommunity of physicians, dentists, and patients with this disease.
otably, cardiovascular conditions that are relatively uncommon in
linical practice and with low event rates (such as HCM) are not
menable to the level of evidence sought by the AHA panel.
owever, just because it is not possible to assemble such evidence
hrough randomized trials does not mean that a significant relation-
hip between antibiotic treatment and prevention of infective endo-
arditis is nonexistent—nor does it mean that it is justified to simply
egate the issue.
Perhaps this would be another matter if the potential benefit of
rophylactic antibiotics were outweighed by the risks of treatment.
owever, as pointed out by Bach (1), and conceded in the AHA
ocument (2), there has never been a documented anaphylactic
eath attributable to antibiotics administered prophylactically to
revent endocarditis. This is consistent with the authors’ combined
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ave taken antibiotics for that purpose.
It is obvious to us that following the most recent AHA
ecommendations and withholding antibiotics from patients with
CM will unavoidably have the effect of unnecessarily creating
everal new cases of infective endocarditis each year. We are at a
oss to understand how these AHA recommendations (2), which
e believe should be revised, are in the best interests of the HCM
atient population.
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e rely on guidelines. When large amounts of data exist, we rely
n expert summaries to distill the data and to make evidence-based
ecommendations. When data are more scarce, we rely on experts
o thoughtfully weigh the existing data along with their own
xperience, balancing risks and benefits, and make recommenda-
ions in the best interest of patient welfare.
It might be said too often, or might be said not often enough,
hat guidelines are . . . only guidelines. It remains imperative, espe-
ially when data are scarce, to understand the nature of guideline
ecommendations, including the presence or absence of data to
upport them. Ultimately, the savvy clinician should help his or her
atients individually weigh the relative risks and benefits of any
iagnostic test, or any therapeutic or prophylactic intervention.
his author thanks Drs. Maron and Lever for their discussion
egarding my paper (1) and for adding their voices to those of other
hysicians who, having cared for patients at risk of or suffering
rom endocarditis, raise concern about the new antibiotic prophy-
axis guidelines (2), ask whether they represent the best balance of
isk versus benefit, and ask whether these recommendations are the
ost likely means to adequately protect our patients (3–5).
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tent Overexpansion
nd Myocardial No-Reflow
arly revascularization of the infarct-related artery by primary
ercutaneous coronary intervention has become the mainstay of
herapy, especially in ST-segment elevation myocardial infarction.hen performed early in the course of acute myocardial infarction,
